Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose trimethoprim-sulfamethoxazole for treatment of Pneumocystis pneumonia in HIV patients
TCTR20250222003Phase 3Not yet recruiting
- Sponsor
- Natthakit Chavapradit
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trimethoprim + sulfamethoxazole in pneumocystis pneumonia (PCP), human immunodeficiency virus infection (HIV), sponsored by Natthakit Chavapradit. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
trimethoprim + sulfamethoxazole
03
Conditions
pneumocystis pneumonia (PCP)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on TCTR20250222003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250222003.